Yüklüyor......
Keyboard: A Novel Bayesian Toxicity Probability Interval Design for Phase I Clinical Trials
The primary objective of phase I oncology trials is to find the maximum tolerated dose (MTD). The 3+3 design is easy to implement but performs poorly in finding the MTD. A newer design, such as the modified toxicity probability interval (mTPI) design, provides better accuracy to identify the MTD but...
Kaydedildi:
| Yayımlandı: | Clin Cancer Res |
|---|---|
| Asıl Yazarlar: | , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
2017
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5554436/ https://ncbi.nlm.nih.gov/pubmed/28546227 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-17-0220 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|